Previous Article | Next Article 
Journal of Virology, March 2002, p. 2730-2738, Vol. 76, No. 6
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.6.2730-2738.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
High-Level Primary CD8+ T-Cell Response to Human Immunodeficiency Virus Type 1 Gag and Env Generated by Vaccination with Recombinant Vesicular Stomatitis Viruses
Karl Haglund,1,2 Ingrid Leiner,3,4,
Kristen Kerksiek,4,
Linda Buonocore,1 Eric Pamer,3,4,
and John K. Rose1,5*
Departments of Pathology,1
Cell Biology,5
Medicine,3
Program in Microbiology,2
Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 065104
Received 26 October 2001/
Accepted 22 December 2001
We investigated the primary cellular immune responses to human immunodeficiency virus type 1 (HIV-1) Env and Gag proteins elicited by recombinant vesicular stomatitis viruses (rVSVs). The primary response to Env peaked 5 to 7 days after intraperitoneal vaccination, at which time 40% of CD8+ cells were Env tetramer positive and activated (CD62LLo). These freshly isolated cells actively lysed target cells pulsed with the p18-I10 peptide and secreted gamma interferon and tumor necrosis factor alpha after stimulation with the Env p18-I10 peptide. The primary response to Env elicited by rVSVs was sixfold higher than that elicited by recombinant vaccinia viruses (rVVs) at 5 days postvaccination. An intranasal route of vaccination with VSV-Env also elicited a strong primary response to Env. The primary immune response to Gag elicited by rVSV peaked 7 days after vaccination, at which time 3% of CD8+ cells were Gag tetramer positive and CD62LLo and functional by intracellular cytokine staining. This response was eightfold higher than that elicited by rVV expressing Gag. VSV-GagEnv, which expresses both Gag and Env from a single recombinant, also induced strong cytotoxic T-lymphocyte (CTL) responses to both Env and Gag. Our quantitative analyses illustrate the potency of the VSV vector system in CTL induction.
* Corresponding author. Mailing address: Departments of Pathology and Cell Biology, Yale University School of Medicine, New Haven, CT 06510. Phone: (203) 785-6794. Fax: (203) 785-7467. E-mail: jrose{at}biomed.med.yale.edu.
Present address: Infectious Diseases Service, Laboratory of Antimicrobial Immunity, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Present address: LMU München, Institut für Immunologie, 803360 Munich, Germany.
Journal of Virology, March 2002, p. 2730-2738, Vol. 76, No. 6
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.6.2730-2738.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Liao, J. B., Publicover, J., Rose, J. K., DiMaio, D.
(2008). Single-Dose, Therapeutic Vaccination of Mice with Vesicular Stomatitis Virus Expressing Human Papillomavirus Type 16 E7 Protein. CVI
15: 817-824
[Abstract]
[Full Text]
-
Rose, N. F., Publicover, J., Chattopadhyay, A., Rose, J. K.
(2008). Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors. Proc. Natl. Acad. Sci. USA
105: 5839-5843
[Abstract]
[Full Text]
-
Cooper, D., Wright, K. J., Calderon, P. C., Guo, M., Nasar, F., Johnson, J. E., Coleman, J. W., Lee, M., Kotash, C., Yurgelonis, I., Natuk, R. J., Hendry, R. M., Udem, S. A., Clarke, D. K.
(2008). Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice. J. Virol.
82: 207-219
[Abstract]
[Full Text]
-
Kohl, W., Grone, A., Moennig, V., Herrler, G.
(2007). Expression of the surface glycoprotein E2 of Bovine viral diarrhea virus by recombinant vesicular stomatitis virus. J. Gen. Virol.
88: 157-165
[Abstract]
[Full Text]
-
Bukreyev, A., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L.
(2006). Nonsegmented negative-strand viruses as vaccine vectors.. J. Virol.
80: 10293-10306
[Full Text]
-
Ahmed, M., Brzoza, K. L., Hiltbold, E. M.
(2006). Matrix Protein Mutant of Vesicular Stomatitis Virus Stimulates Maturation of Myeloid Dendritic Cells. J. Virol.
80: 2194-2205
[Abstract]
[Full Text]
-
Stone, G. W., Barzee, S., Snarsky, V., Kee, K., Spina, C. A., Yu, X.-F., Kornbluth, R. S.
(2006). Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines. J. Virol.
80: 1762-1772
[Abstract]
[Full Text]
-
Ramsburg, E., Publicover, J., Buonocore, L., Poholek, A., Robek, M., Palin, A., Rose, J. K.
(2005). A Vesicular Stomatitis Virus Recombinant Expressing Granulocyte-Macrophage Colony-Stimulating Factor Induces Enhanced T-Cell Responses and Is Highly Attenuated for Replication in Animals. J. Virol.
79: 15043-15053
[Abstract]
[Full Text]
-
Publicover, J., Ramsburg, E., Rose, J. K.
(2005). A Single-Cycle Vaccine Vector Based on Vesicular Stomatitis Virus Can Induce Immune Responses Comparable to Those Generated by a Replication-Competent Vector. J. Virol.
79: 13231-13238
[Abstract]
[Full Text]
-
Publicover, J., Ramsburg, E., Rose, J. K.
(2004). Characterization of Nonpathogenic, Live, Viral Vaccine Vectors Inducing Potent Cellular Immune Responses. J. Virol.
78: 9317-9324
[Abstract]
[Full Text]
-
Giri, M., Ugen, K. E., Weiner, D. B.
(2004). DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade. Clin. Microbiol. Rev.
17: 370-389
[Abstract]
[Full Text]
-
Roberts, A., Reuter, J. D., Wilson, J. H., Baldwin, S., Rose, J. K.
(2004). Complete Protection from Papillomavirus Challenge after a Single Vaccination with a Vesicular Stomatitis Virus Vector Expressing High Levels of L1 Protein. J. Virol.
78: 3196-3199
[Abstract]
[Full Text]
-
Nayak, B. P., Sailaja, G., Jabbar, A. M.
(2003). Enhancement of gp120-Specific Immune Responses by Genetic Vaccination with the Human Immunodeficiency Virus Type 1 Envelope Gene Fused to the Gene Coding for Soluble CTLA4. J. Virol.
77: 10850-10861
[Abstract]
[Full Text]
-
McGettigan, J. P., Naper, K., Orenstein, J., Koser, M., McKenna, P. M., Schnell, M. J.
(2003). Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. J. Virol.
77: 10889-10899
[Abstract]
[Full Text]
-
Okuma, K., Dalton, K. P., Buonocore, L., Ramsburg, E., Rose, J. K.
(2003). Development of a Novel Surrogate Virus for Human T-Cell Leukemia Virus Type 1: Inhibition of Infection by Osteoprotegerin. J. Virol.
77: 8562-8569
[Abstract]
[Full Text]
-
Harvey, T. J., Anraku, I., Linedale, R., Harrich, D., Mackenzie, J., Suhrbier, A., Khromykh, A. A.
(2003). Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development. J. Virol.
77: 7796-7803
[Abstract]
[Full Text]
-
Sailaja, G., Husain, S., Nayak, B. P., Jabbar, A. M.
(2003). Long-Term Maintenance of gp120-Specific Immune Responses by Genetic Vaccination with the HIV-1 Envelope Genes Linked to the Gene Encoding Flt-3 Ligand. J. Immunol.
170: 2496-2507
[Abstract]
[Full Text]
-
Haglund, K., Leiner, I., Kerksiek, K., Buonocore, L., Pamer, E., Rose, J. K.
(2002). Robust Recall and Long-Term Memory T-Cell Responses Induced by Prime-Boost Regimens with Heterologous Live Viral Vectors Expressing Human Immunodeficiency Virus Type 1 Gag and Env Proteins. J. Virol.
76: 7506-7517
[Abstract]
[Full Text]
Copyright © 2002 by the American Society for Microbiology. All rights reserved.